LUAD EAM Sub-cohort: Altered antiporter activity, especially the cystine/glutamate antiporter SLC7A11, supports redox homeostasis and therapy resistance, linking transporter up-regulation to tumor growth and metastatic potential in NSCLC [50,51]. The gene discussed is SLC7A11; the disease is neoplasm.